Results 91 to 100 of about 516,620 (290)

T-cell Bispecific Antibodies Suppress Multiple Myeloma

, 2017
T-cell bispecific antibodies (TCB) targeting BCMA or FcRH5 induce T cell–mediated myeloma cell death.

core   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Purification of anti-BSA-digoxin bispecific antibodies.

, 2013
Anti-BSA-digoxin bispecific antibodies were purified from the serum using a series of purification methods. IgG fraction was obtained using 50% saturated ammonium sulfate precipitation, followed by passing through a protein A column.
Jinming Li (128865), Wei Wang (17594), Ruihuan Xu (364030)   +2 more
core   +1 more source

From Prediction to Decision Making: PBPK and QSP as Regulatory‐Grade NAMs

Clinical Pharmacology &Therapeutics, EarlyView.
New approach methodologies (NAMs) encompass a diverse and rapidly evolving set of experimental and computational tools designed to generate human‐relevant mechanistic data for use in drug development and regulatory decision making. Experimental NAMs provide insights into drug disposition, pharmacological activity, and disease biology that are difficult
Karen Rowland Yeo, Piet H. van der Graaf
wiley   +1 more source

Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies

Frontiers in Immunology
Bispecific T-cell-engaging antibodies are a growing class of therapeutics with numerous molecules being tested in clinical trials and, currently, seven of them have received market approval.
Nishant Mohan, Safiat Ayinde, Hanjing Peng, Shraboni Dutta, Yi Shen, Vincent M. Falkowski, Thomas G. Biel, Tongzhong Ju, Wen Jin Wu   +8 more
doaj   +1 more source

Bispecific antibodies for viral immunotherapy

Human Vaccines & Immunotherapeutics, 2017
Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies.
Elisabeth K. Nyakatura, Alexandra Y. Soare, Jonathan R. Lai   +2 more
doaj   +1 more source

Influence of bispecific antibodies on the in vitro bactericidal activity of bovine neutrophils against Staphylococcus aureus

, 2000
We conducted the following study to determine if bispecific antibodies enhance the bactericidal activity of bovine neutrophils. Bispecific antibodies were synthesized by chemically crosslinking bovine neutrophil monoclonal antibodies to Staphylococcus ...
Poultrel, B, M.J. Paape, Wang, Y, G.M. Tomita, B. Poultrel, P. Rainard, Paape, Max, Rainard, P, Y. Wang, Tomita, GM   +9 more
core   +1 more source

From Biological Mechanisms to Causal Inference: Quantitative Systems Pharmacology and Causal Frameworks in Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Digital patients and in silico clinical trials offer new opportunities to advance pharmacological research, clinical development, and regulatory decision‐making by enabling the simulation of treatment effects prior to testing in patients. Among the most promising of these opportunities is the combined use of quantitative systems pharmacology (QSP) and ...
Thomas Klabunde, Ramon Hernandez, Piet H. van der Graaf, Tommaso Andreani   +3 more
wiley   +1 more source

Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies

mAbs
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific IgG ...
Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter   +15 more
doaj   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source